China online Medical B2B, Global trade platform!
企业入驻 My member Message Center
International
  • English
  • العربية
  • Русский
  • Español
  • Français
  • India
Products
sign in
join free
Join Free
CapitalBio Technology Co., Ltd.
verified Copper Member

CapitalBio Technology Co., Ltd.

Beijing,China

home product company profile Certifications Exhibition contact

CapitalBio Technology Co., Ltd.

Beijing,China

favorite supplier

verified Copper Member
home product company profile Certifications contact
CapitalBio Technology Co., Ltd.
favorite supplier
verified Copper Member

CapitalBio Technology Co., Ltd.

Beijing,China

Scan QR code

Access to mobile station

home product company profile Certifications contact
Compare
Clear All
Alternate Text

CapitalBio Non-Invasive Prenatal Testing (NIPT) for Fetal Chromosomal Aneuploidies

FOB Price : Get a Price/Quote

Min.Order : 1 Set(s)

Certification : CE

Brand Name : CapitalBio Technology

Payment Terms : L/C,T/T

contact now Video Conference

favorite

share :

product information

  • brand name : CapitalBio Technology

  • certification : CE

  • min.order : 1 Set(s)

  • warranty : \

  • payment terms : L/C,T/T

  • Packaging : Carton

  • Specification : \

  • place of origin : Beijing

product description

NIPT consists of three reagents:
  1. Nucleic acid extraction/purification kit (Art No. S10020)
  2. Fetal aneuploidies(trisomy21, trisomy18 and trisomy13) detection kit (Art No. S30030)
  3. Sequencing reaction universal kit (Art No. S10010)

Product introduction:
By extracting fetal free DNA maternal peripheral blood, with a new generation of high-throughput sequencing technology, and combined with bioinformation analysis, chromosome abnormalities, such as trisomy 21, 13 and 18, can be detected simultaneously

Who should be offered CapitalBio NIPT?
  1. Pregnant women with indicators suggesting high risk of fetal aneuploidies who wish to have an early and accurate test. The indicators include:
  1. High maternal age
  2. Positive result in serum screening
  3. Abnormalities discovered in ultrasonography
  4. History of giving birth to a baby/babies with chromosomal abnormality(ies)
  5. Parental abnormality(ies) involving one of the tested chromosomes
  1. Pregnant women with interventional prenatal diagnosis contraindications (threatened abortion, fever, bleeding tendency, unrecovered infection, etc.)
  2. Pregnant women with gestational age of above 20+6 weeks, who have missed the best time for serological screening

Why CapitalBio NIPT?
  1. High Accuracy: conventional screening methods 60-80%, the accuracy rate of CapitalBio NIPT 99%
  2. Low risk of miscarriage: conventional screening methods 0.2%-1%, the risk of miscarriage associated with NIPT is 0
  3. Short turnaround time: G-band karyotyping at least one week, complete NIPT workflow 4 days

Method
The CapitalBio NIPT based on semiconductor sequencing technology offers a wide range of applications and also ensures a more cost-effective and rapid analysis

People who viewed this also viewed

  • Fully Integrated Automatic On-site DNA Quick Test System

    FOB Price :

    Min.Order : 1 Piece(s)

  • COVID-19 (SARS-CoV-2) Nucleic Acid Test Kit (Fluorescence PCR Method)

    FOB Price :

    Min.Order : 1 Piece(s)

  • CapitalBio OP AldehydeSlideTM

    FOB Price :

    Min.Order : 1 Piece(s)

  • Fully Automatic Multi-index Pathogen Nucleic Acid Detection System

    FOB Price :

    Min.Order : 1 Piece(s)

  • CapitalBio Non-Invasive Prenatal Testing (NIPT) for Fetal Chromosomal Aneuploidies

    FOB Price :

    Min.Order : 1 Set(s)

CapitalBio Technology Co., Ltd.

Copper verified

Business Type Manufacturer

Country / Region Beijing,China

Main Products Chinese Medical Instruments, Molecular Biology Reagents, POCT Diagnostic Reagents, Disposables & Consumables, Laboratory Instruments

Main Markets

You May Like

CapitalBio Non-Invasive Prenatal Testing (NIPT) for Fetal Chromosomal Aneuploidies
share :

contact now

product information

product description

NIPT consists of three reagents:
  1. Nucleic acid extraction/purification kit (Art No. S10020)
  2. Fetal aneuploidies(trisomy21, trisomy18 and trisomy13) detection kit (Art No. S30030)
  3. Sequencing reaction universal kit (Art No. S10010)

Product introduction:
By extracting fetal free DNA maternal peripheral blood, with a new generation of high-throughput sequencing technology, and combined with bioinformation analysis, chromosome abnormalities, such as trisomy 21, 13 and 18, can be detected simultaneously

Who should be offered CapitalBio NIPT?
  1. Pregnant women with indicators suggesting high risk of fetal aneuploidies who wish to have an early and accurate test. The indicators include:
  1. High maternal age
  2. Positive result in serum screening
  3. Abnormalities discovered in ultrasonography
  4. History of giving birth to a baby/babies with chromosomal abnormality(ies)
  5. Parental abnormality(ies) involving one of the tested chromosomes
  1. Pregnant women with interventional prenatal diagnosis contraindications (threatened abortion, fever, bleeding tendency, unrecovered infection, etc.)
  2. Pregnant women with gestational age of above 20+6 weeks, who have missed the best time for serological screening

Why CapitalBio NIPT?
  1. High Accuracy: conventional screening methods 60-80%, the accuracy rate of CapitalBio NIPT 99%
  2. Low risk of miscarriage: conventional screening methods 0.2%-1%, the risk of miscarriage associated with NIPT is 0
  3. Short turnaround time: G-band karyotyping at least one week, complete NIPT workflow 4 days

Method
The CapitalBio NIPT based on semiconductor sequencing technology offers a wide range of applications and also ensures a more cost-effective and rapid analysis
CapitalBio Technology Co., Ltd.
verified 1

Recommend

Sign in

Forgot Password ?
Sign in join free

Join Free

Create New Account

Leave your contact information for the suppliers. If you're our member, Please Sign In to use your account information.

Sign in
Sign In Join Free